Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 19,140,000 shares, an increase of 11.0% from the October 31st total of 17,250,000 shares. Currently, 18.5% of the company’s stock are short sold. Based on an average trading volume of 3,040,000 shares, the short-interest ratio is presently 6.3 days.

Wall Street Analyst Weigh In

HUMA has been the topic of several analyst reports. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Thursday, November 21st. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Humacyte in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $13.00.

Humacyte Price Performance

HUMA stock traded down $0.07 during midday trading on Monday, reaching $4.45. The company had a trading volume of 2,802,231 shares, compared to its average volume of 2,415,096. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The company has a market capitalization of $560.07 million, a price-to-earnings ratio of -3.37 and a beta of 1.47. The stock has a 50 day moving average price of $5.22 and a 200-day moving average price of $6.16. Humacyte has a 1-year low of $2.45 and a 1-year high of $9.97.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the transaction, the chief executive officer now directly owns 2,419,712 shares in the company, valued at $10,743,521.28. The trade was a 25.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,662,886 shares of company stock valued at $7,489,538. Insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Humacyte during the first quarter valued at about $197,000. ARS Investment Partners LLC bought a new stake in shares of Humacyte during the second quarter worth about $559,000. Bank of New York Mellon Corp raised its holdings in Humacyte by 62.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock valued at $1,219,000 after buying an additional 97,931 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in Humacyte during the 2nd quarter worth approximately $83,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.